机构：[1]Hongqiao International Institute of Medicine, Shanghai Tongren Hospital and School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.[2]Department of Preventive and Health Care, Tianjin Union Medical Center, Nankai University, Tianjin, China.[3]Department of Colorectal Surgery, Tianjin Union Medical Center, Nankai University, Tianjin, China.[4]Colorectal Cancer Screening Office, Tianjin Institute of Coloproctology, Tianjin, China.[5]Department of Colorectal Surgery, Tianjin Hospital, Tianjin, China.[6]Department of Pathology, Tianjin Union Medical Center, Nankai University, Tianjin, China.[7]Cancer Prevention Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.[8]NCDs Preventive Department, Tianjin Centers for Disease Control and Prevention, Tianjin, China.[9]Laboratory of Oncologic Molecular Medicine, Tianjin Union Medical Center, Nankai University, Tianjin, China.[10]Shanghai Clinical Research Promotion and Development Center, Shanghai Hospital Development Center, Shanghai, China.
To evaluate the effectiveness of fecal immunochemical testing (FIT) in colorectal cancer screening.We conducted a prospective cohort study among 5,598 participants age 40-74 years between 2012 and 2020 in Tianjin, China. Inverse probability weighting was adopted to adjust for potential imbalanced factors between groups. A Cox proportional hazards model was used to estimate the weighted associations between FIT screening and advanced colorectal neoplasia. A difference-in-difference (DID) model was adopted to compare the incidence rates of advanced colorectal neoplasia between groups.In DID analysis, the rate of incidence was reduced by 0.34 cases per person-years in the screening group as compared with the historical FIT screening group (rate ratio [RR], 0.08 [95% CI, 0.07 to 0.10]) and by 0.06 cases per person-years in the non-FIT screening group as compared with the historical non-FIT screening group (RR, 0.37 [95% CI, 0.29 to 0.48]; P < .001 for both comparisons), with a relative reduction of 0.28. Similar benefit effect from FIT screening was observed in sex and age subgroups.FIT screening was associated with a reduction in incidence density from advanced colorectal neoplasia.
基金：
Supported by the National Natural Science Foundation of China (Grant
No. 81973135 and Grant No. 81972826) and Science and Technology
Commission of Shanghai Municipality (Grant No. 21XD1402600).
第一作者机构：[1]Hongqiao International Institute of Medicine, Shanghai Tongren Hospital and School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
共同第一作者：
通讯作者：
通讯机构：[1]Hongqiao International Institute of Medicine, Shanghai Tongren Hospital and School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.[10]Shanghai Clinical Research Promotion and Development Center, Shanghai Hospital Development Center, Shanghai, China.[*1]Hongqiao International Institute of Medicine,Shanghai Tongren Hospital and Faculty of Public Health, Shanghai Jiao Tong University School of Medicine, 227 South Chongqing Rd, Shanghai 200025, China
推荐引用方式(GB/T 7714)：
Zhang Guanglu,Wang Yiying,Zhao Lizhong,et al.Fecal Immunochemical Testing and the Risk of Advanced Colorectal Neoplasia: A Difference-In-Difference Analysis[J].JCO Global Oncology.2024,10:e2300188.doi:10.1200/GO.23.00188.
APA：
Zhang Guanglu,Wang Yiying,Zhao Lizhong,Zhang Mingqing,Zhang Weihua...&Zhang Xipeng.(2024).Fecal Immunochemical Testing and the Risk of Advanced Colorectal Neoplasia: A Difference-In-Difference Analysis.JCO Global Oncology,10,
MLA：
Zhang Guanglu,et al."Fecal Immunochemical Testing and the Risk of Advanced Colorectal Neoplasia: A Difference-In-Difference Analysis".JCO Global Oncology 10.(2024):e2300188
